Holst JJ. From the Incretin concept and the discovery of GLP-1 to Today’s Diabetes Therapy. Front Endocrinol. 2019;10:260.

Article  Google Scholar 

Raben A, Tagliabue A, Astrup A. The reproducibility of subjective appetite scores. Br J Nutr. 1995;73:517–30.

Article  CAS  PubMed  Google Scholar 

Flint A, Raben A, Blundell JE, Astrup A. Reproducibility, power and validity of visual analogue scales in assessment of appetite sensations in single test meal studies. Int J Obes. 2000;23:38–48.

Article  Google Scholar 

Turton MD, O’Shea D, Gunn I, Beak SA, Edwards CM, Meeran K, et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature. 1996;379:69–72.

Article  CAS  PubMed  Google Scholar 

Tang-Christensen M, Larsen PJ, Göke R, Fink-Jensen A, Jessop DS, Møller M, et al. Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats. Am J Physiol. 1996;271:R848–56.

CAS  PubMed  Google Scholar 

Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest. 1998;101:515–20.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Holst JJ; Astrup AV; Judge ME; Knudsen LB; Thim L; Wulff BS Use of GLP-peptides. Treatment of diseases associated with impaired appetite regulation e.g. obesity - by administration of the proglucagon fragment GLP-1(1-45), or its fragment, analogue or amide. Filed by Novo Nordisk A/S. Priority date: 12 November 1996. Patent EP0941114(B1)/23 February 2005.

Näslund E, Gutniak M, Skogar S, Rössner S, Hellström PM. Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men. Am J Clin Nutr. 1998;68:525–30.

Article  PubMed  Google Scholar 

Gutzwiller JP, Göke B, Drewe J, Hildebrand P, Ketterer S, Handschin D, et al. Glucagon-like peptide-1: a potent regulator of food intake in humans. Gut. 1999;44:81–86.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Flint A, Raben A, Ersbøll AK, Holst JJ, Astrup A. The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity. Int J Obes. 2001;25:781–92.

Article  CAS  Google Scholar 

Verdich C, Flint A, Gutzwiller J-P, Näslund E, Beglinger C, Hellström PM, et al. A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. J Clin Endocrinol Metab. 2001;86:4382–9.

CAS  PubMed  Google Scholar 

Belza A, Ritz C, Sørensen MQ, Holst JJ, Rehfeld JF, Astrup A. Contribution of gastroenteropancreatic appetite hormones to protein-induced satiety. Am J Clin Nutr. 2013;97:980–9.

Article  CAS  PubMed  Google Scholar 

Flint A, Raben A, Rehfeld JF, Holst JJ, Astrup A. The effect of glucagon-like peptide-1 on energy expenditure and substrate metabolism in humans. Int J Obes. 2000;24:288–98.

Article  CAS  Google Scholar 

Astrup A, Rössner S, Van Gaal L, Rissanen A, Niskanen L, Al Hakim M, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet. 2009;374:1606–16.

Article  CAS  PubMed  Google Scholar 

Astrup A, Carraro R, Finer N, Harper A, Kunesova M, Lean ME, et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes. 2012;36:843–54.

Article  CAS  Google Scholar 

Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, et al. A randomized, controlled trial of 3.0 mg of Liraglutide in weight management. N Engl J Med. 2015;373:11–22.

Article  PubMed  Google Scholar 

Lincoff AM, SELECT Trial Investigators. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389:2221–32.

Article  CAS  PubMed  Google Scholar 

Sandoval DA, D’Alessio DA. Physiology of proglucagon peptides: role of glucagon and GLP-1 in health and disease. Physiol Rev. 2015;95:513–48.

Article  CAS  PubMed  Google Scholar 

Harder H, Nielsen L, Tu DT, Astrup A. The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes. Diabetes Care. 2004;27:1915–21.

Article  CAS  PubMed  Google Scholar 

Dixit AA, Bateman BT, Hawn MT, Odden MC, Sun EC. Preoperative GLP-1 receptor agonist use and risk of postoperative respiratory complications. JAMA. Published online April 22, 2024. https://doi.org/10.1001/jama.2024.5003.

Krog-Mikkelsen I, Sloth B, Dimitrov D, Tetens I, Björck I, Flint A, et al. A low glycemic index diet does not affect postprandial energy metabolism but decreases postprandial insulinemia and increases fullness ratings in healthy women. J Nutr. 2011;141:1679–84.

Article  CAS  PubMed  Google Scholar 

Larsen TM, Dalskov SM, van Baak M, Jebb SA, Papadaki A, Pfeiffer AF, et al. Diets with high or low protein content and glycemic index for weight-loss maintenance. N Engl J Med. 2010;363:2102–13.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Livesey G, Taylor R, Livesey HF, Buyken AE, Jenkins DJA, Augustin LSA, et al. Dietary Glycemic Index and load and the risk of Type 2 Diabetes: Assessment of causal relations. Nutrients. 2019;11:1436.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gögebakan O, Kohl A, Osterhoff MA, van Baak MA, Jebb SA, Papadaki A, et al. Effects of weight loss and long-term weight maintenance with diets varying in protein and glycemic index on cardiovascular risk factors: the diet, obesity, and genes (DiOGenes) study: a randomized, controlled trial. Circulation. 2011;124:2829–38.

Article  PubMed  Google Scholar 

Dwivedi AK, Dubey P, Reddy SY, Clegg DJ. Associations of Glycemic Index and Glycemic Load with cardiovascular disease: updated evidence from meta-analysis and cohort studies. Curr Cardiol Rep. 2022;24:141–61.

Article  PubMed  Google Scholar 

Jenkins DJ, Wolever TM, Collier GR, Ocana A, Rao AV, Buckley G, et al. Metabolic effects of a low-glycemic-index diet. Am J Clin Nutr. 1987;46:968–75.

Article  CAS  PubMed  Google Scholar 

Miller JC. Importance of glycemic index in diabetes. Am J Clin Nutr. 1994;59:747S–752S.

Article  CAS  PubMed  Google Scholar 

Kuwata H, Yabe D, Murotani K, Fujiwara Y, Haraguchi T, Kubota S, et al. Effects of glucagon-like peptide-1 receptor agonists on secretions of insulin and glucagon and gastric emptying in Japanese individuals with type 2 diabetes: A prospective, observational study. J Diabetes Investig. 2021;12:2162–71.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Taylor R, Al-Mrabeh A, Zhyzhneuskaya S, Peters C, Barnes AC, Aribisala BS, et al. Remission of Human Type 2 diabetes requires decrease in liver and pancreas fat content but is dependent upon capacity for β cell recovery. Cell Metab. 2018;28:547–e3.

Article  CAS  PubMed  Google Scholar 

Gagnon Eloi, Mitchell PatriciaL, Arsenault BenoitJ. Body fat distribution, fasting insulin levels, and insulin secretion: A bidirectional mendelian randomization study. J Clin Endocrin Metab. 2023;108:1308–17.

Article  Google Scholar 

Shi Q, Nong K, Vandvik PO, Guyatt GH, Schnell O, Rydén L, et al. Benefits and harms of drug treatment for type 2 diabetes: Systematic review and network meta-analysis of randomised controlled trials. BMJ. 2023;381:e074068.

Article  PubMed  PubMed Central  Google Scholar 

Ludwig DS, Holst JJ. Childhood obesity at the crossroads of science and social justice. JAMA. 2023;329:1909–10.

Article  PubMed  Google Scholar